Take a Chill Pill
Pharmaceutical Executive
In the spirit of lawn chair cogitation and hammock-spun reverie, Pharm Exec invites you to submit your own verses-pharma-related, of course-to be published on our website in late August.
The "tawny streaks and shades" of summer sunlight, as Walt Whitman put it, have a mellowing effect; leisurely hours spent in scenic locales, on vacation or just out on the weekend, provide an opportunity for unhurried thought and easy reflection ("heat dome" notwithstanding). In the spirit of lawn chair cogitation and hammock-spun reverie, Pharm Exec invites you to submit your own verses—pharma-related, of course—to be published on our website in late August. Send those jottings from the post-conference tarmac, the hotel bar, or the family vacation to bcomer@advanstar.com, if you are so inclined. Our pseudonymous colleague Stix Daley has contributed one of his recent scribblings to kick things off. Summer will be gone soon, so take it slow while you can, and enjoy.
Pharmacopoeticsby Stix Daley
Longitudinal studies on red meat with clever endpoints.
Freedom to choose cigarettes and their adverse events.
By QALY, I develop the best immunity
I mean by golly.
Policy and people need most toexpire—
in their due time of course.
Meantime I’ve mislaid the data
that I
well I guess that I
ought to report.
Fee-for-service reimagined as
Hippocratical aphorism.
A cunning caduceus loosed
in the waiting room.
To Asclepius’s chagrin.
Even our immune systems are uniting
in mutiny
Coffee cup copays a fair market value
or just an encephalographic
image problem.
Commodities traders and doctors
know better.
Or regular Tories.
I mean no better.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
